Aripiprazole in the Treatment of Patients With Schizophrenia & Symptoms of

Status Completed

Clinical Trial Summary

To evaluate the effectiveness of flexible doses (15-30mg) of Aripiprazole in the treatment of patients with schizophrenia and co-morbid symptoms of OCD in the outpatient setting. The overall effectiveness of Aripiprazole will be evaluated by use of the Brief Psychiatric Rating Scale(BPRS), Yale-Brown OCD scale and Clinical Global Impression-Improvement(CGI-I) scale.

Clinical Trial Description

Symptoms of OCD is a rather common co-morbid condition in patients with Schizophrenia. Some studies suggest that obsessive-compulsive symptoms may be present in 7.8-46% of schizophrenic patients and who seem to be poorly responsive to drug therapy. The serotonergic medications in combination with cognitive-behavioral therapy stil remain the preferred treatment for OCD symptoms. There are controversial data regarding effect of neuroleptics on symptoms of OCD. It was noted that the use of Risperdone, Quatiapine and Clozapine might aggravate OCD symptoms. Serotonin antagonism of these neuroleptics is believed to exacerbate obsessive-compulsive symptoms in schizophrenia. On the other hand, Pourovsky M. at(2000) reported three cases of Schizophrenia with symptoms of OCD successfully treated with Olanzapine.One of our patients with Schizophrenia and co-morbid symptoms of OCD who was unsuccessfully treated with various neuroleptics in combination with anti-obsessive agents,demonstrated significant improvement in both Schizophrenic and obsessive compulsive symptoms after she was switched to Aripiprazole. This result encouraged us to initiate pilot study of effectiveness of Aripiprazole in the treatment of specific population of schizophrenic patients with symptoms of OCD. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00374348
Study type	Interventional
Source	Jamaica Hospital Medical Center
Contact
Status	Completed
Phase	N/A
Start date	March 2005
Completion date	May 2008

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04631042` - Developing Brain, Impulsivity and Compulsivity
Completed	`NCT02855580` - Integrating Pharmacogenomic Testing Into a Child Psychiatry Clinic
Completed	`NCT02229903` - An Evaluation of the Safety and Efficacy of the dTMS Treatment for OCD	N/A
Completed	`NCT02202915` - CBT for Pediatric OCD: Community Training Pilot	N/A
Completed	`NCT01794156` - Evaluation of a Cognitive Therapy (Inference-based-therapy) for the Treatment of Obsessional Compulsive Disorder	N/A
Completed	`NCT02089984` - Web Based Therapist Training on Cognitive Behavior Therapy for Anxiety Disorders	N/A
Completed	`NCT01348529` - Internet Cognitive Behavior Therapy (CBT) for Obsessive Compulsive Disorder (OCD)	N/A
Recruiting	`NCT00965211` - Evaluation of the HBDL Coil Transcranial Magnetic Stimulation (TMS) Device - Safety and Feasibility Study for the Treatment of Tourette Syndrome	N/A
Completed	`NCT01172873` - D-Cycloserine Augmentation to CBT With Exposure and Response Prevention in Adults and Adolescents With OCD	N/A
Completed	`NCT00723060` - Comparison of Effects Between Conventional Dose and High Dose Escitalopram on Clinical Improvement in Patients With Obsessive-compulsive Disorder	Phase 4
Not yet recruiting	`NCT00743834` - Cost-Effectiveness of Adding Web-Based Cognitive-Behavioral Therapy (CBT) to Luvox CR for Obsessive Compulsive Disorder (OCD)	Phase 4
Completed	`NCT02421315` - Overlapping Neural Circuits in Pediatric OCD	N/A
Completed	`NCT02194075` - Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder	Phase 4
Completed	`NCT01981317` - Stepped Care Cognitive Behavioral Therapy for Pediatric Obsessive Compulsive Disorder	N/A
Completed	`NCT01686087` - Attaining and Maintaining Wellness in Obsessive-compulsive Disorder	N/A
Completed	`NCT01331876` - Modification of Cerebral Activity of Obsessive Compulsive Disorder (OCD) Patients During Cognitive and Behavioral Therapy	N/A
Terminated	`NCT00997087` - A Randomized, Double-Blind, Placebo-Controlled Trial of Flumazenil for the Treatment of Obsessive Compulsive Disorder	Phase 2
Completed	`NCT00533806` - Comparing the Effectiveness of Two Family-based Therapies in Treating Young Children With Obsessive-Compulsive Disorder	Phase 3
Completed	`NCT00517244` - Evaluating Parenting Styles and Child Temperament Associated With Child Anxiety Disorders	N/A
Completed	`NCT00169377` - Subthalamic Nucleus (STN) Stimulation and Obsessive-Compulsive Disorder (OCD)	Phase 1/Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Aripiprazole in the Treatment of Patients With Schizophrenia and Symptoms of Obsessive Compulsive Disorder (OCD)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms